Barclays Downgrades Esperion Therapeutics (ESPR) to Equalweight
Tweet
Share
E-mail
Get Alerts ESPR Hot Sheet
Price: $3.18 --0%
Rating Summary:
6 Buy, 14 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
6 Buy, 14 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Barclays downgraded Esperion Therapeutics (NASDAQ: ESPR) from Overweight to Equalweight with a price target of $13.00 (from $28.00).
For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.
Shares of Esperion Therapeutics closed at $9.66 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Downgrades Renault SA (RNO:FP) (RNSDF) to Equalweight
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
- MidCap Financial Investment Corp (MFIC) PT Lowered to $9.50 at BofA Securities
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
